83. Bittigau P., et al. Antiepileptic drugs and apoptotic neurodegeneration in the developing brain. Proc Natl Acad Sci USA. 2002; 99: 15 089–94.
84. Forcelli P.A., Kim J., Kondratyev A., Gale K. Pattern of antiepileptic drug-induced cell death in limbic regions of the neonatal rat brain. Epilepsia. 2011; 52: e207–11.
85. Zhou K.Q., et al. Treating seizures after hypoxic-ischemic encephalopathy-current controversies and future directions. Int J Mol Sci. 2021; 22: 7121.
86. Kilicdag H., et al. The effect of levetiracetam on neuronal apoptosis in neonatal ratmodel of hypoxic ischemic brain injury. Early Hum Dev. 2013; 89: 355–60.
87. Komur M., et al. Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats. Childs Nerv Syst. 2014; 30: 1001–9.
88. Gonzalez F.F., et al. Erythropoietin increases neurogenesis and oligodendrogliosis of subventricular zone precursor cells after neonatal stroke. Stroke. 2013; 44: 753–8.
89. Shingo T., Sorokan S.T., Shimazaki T., Weiss S. Erythropoietin regulates the in vitro and in vivo production of neuronal progenitors by mammalian forebrain neural stem cells. J Neurosci. 2001; 21: 9733–43.
90. O’Dea M.I. et al. Altered cytokine endotoxin responses in neonatal encephalopathy predict MRI outcomes. Front Pediatr. 2021; 9: 734540.
91. O’Hare F.M., et al. Serial cytokine alterations and abnormal neuroimaging in newborn infants with encephalopathy. Acta Paediatr. 2017; 106: 561–7.
92. Ruth V., Widness J.A., Clemons G., Raivio K.O. Postnatal changes in serum immunoreactive erythropoietin in relation to hypoxia before and after birth. J Pediatr. 1990; 116: 950–4.
93. Hagag A.A., El Frargy M.S., Abd El-Latif A.E. Study of cord blood erythropoietin, leptin and adiponectin levels in neonates with hypoxic ischemic encephalopathy. Endocr Metab Immune Disord Drug Targets. 2020; 20: 213–20.
94. Teramo K.A., Klemetti M.M., Widness J.A. Robust increases in erythropoietin production by the hypoxic fetus is a response to protect the brain and other vital organs. Pediatr Res. 2018; 84: 807–12.
95. van der Kooij M.A., Groenendaal F., Kavelaars A., Heijnen C.J., van Bel F. Neuroprotective properties and mechanisms of erythropoietin in in vitro and in vivo experimental models for hypoxia/ischemia. Brain Res Rev. 2008; 59: 22–33.
96. Kellert B.A., McPherson R.J., Juul S.E. A comparison of high-dose recombinant erythropoietin treatment regimens in brain-injured neonatal rats. Pediatr Res. 2007; 61: 451–5.
97. Weber A., et al. Neuronal damage after moderate hypoxia and erythropoietin. Neurobiol Dis. 2005; 20: 594–600.
98. Juul S.E., et al. Erytropoietin concentrations in cerebrospinal fluid of nonhuman primates and fetal sheep following high-dose recombinant erythropoietin. Biol Neonate. 2004; 85: 138–44.
99. Statler P.A., McPherson R.J., Bauer L.A., Kellert B.A., Juul S.E. Pharmacokinetics of high-dose recombinant erythropoietin in plasma and brain of neonatal rats. Pediatr Res. 2007; 61: 671–5.
100. Wassink G., et al. Recombinant erythropoietin does not augment hypothermic white matter protection after global cerebral ischaemia in near-term fetal sheep. Brain Commun. 2021; 3: fcab172.
101. Wassink G., et al. Non-additive effects of adjunct erythropoietin therapy with therapeutic hypothermia after global cerebral ischaemia in near-term fetal sheep. J Physiol. 2020; 598: 999–1015.
102. Malla R.R., Asimi R., Teli M.A., Shaheen F., Bhat M.A. Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol. 2017; 37: 596–601.
103. Zhu C., et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics. 2009; 124: e218–26.
104. Wu Y.W., et al. High-dose erythropoietin and hypothermia for hypoxic-ischemic encephalopathy: a phase II trial. Pediatrics. 2016; 137: e20160191.
105. Massaro A.N., et al. Plasma biomarkers of brain injury in neonatal hypoxicischemic encephalopathy. J Pediatr. 2018; 194: 67.e61–75.e61.
106. Wu Y.W., et al. Trial of erythropoietin for hypoxic-ischemic encephalopathy in newborns. N Engl J Med. 2022; 387: 148–59.
107. University of Sidney, National Health and Medical Research Council, Australia. PAEAN – Erythropoietin for Hypoxic Ischaemic Encephalopathy in Newborns. 2016. URL: https://clinicaltrials.gov/ct2/show/NCT03079167
108. University of Utah, Darbe Administration in Newborns Undergoing Cooling for Encephalopathy. 2015. URL: https://clinicaltrials.gov/ct2/show/NCT01471015
109. University of New M. & University of U. Mild Encephalopathy in the Newborn Treated With Darbepoetin. 2021. URL: https://clinicaltrials.gov/ct2/show/NCT03071861
110. Kurtzberg J. A history of cord blood banking and transplantation. Stem Cells Transl Med. 2017; 6: 1309–11.
111. Wang X., et al. Effect of umbilical cord mesenchymal stromal cells on motor functions of identical twins with cerebral palsy: pilot study on the correlation of efficacy and hereditary factors. Cytotherapy. 2015; 17: 224–31.
112. Wang Y., Chen X., Cao W., Shi Y. Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications. Nat Immunol. 2014; 15: 1009–16.
113. Cunningham C.J., Redondo-Castro E., Allan S.M. The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke. J Cereb Blood Flow Metab. 2018; 38: 1276–92.
114. Fisher S.A., et al. Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition. Cochrane Database Syst Rev. 2019; 1: CD009768.
115. Vaes J.E.G., et al. The potential of stem cell therapy to repair white matter injury in preterm infants: lessons learned from experimental models. Front Physiol. 2019; 10: 540.
116. Vu Q., Xie K., Eckert M., Zhao W., Cramer S.C. Meta-analysis of preclinical studies of mesenchymal stromal cells for ischemic stroke. Neurology. 2014; 82: 1277–86.
117. Meier C., et al. Spastic paresis after perinatal brain damage in rats is reduced by human cord blood mononuclear cells. Pediatr Res. 2006; 59: 244–9.
118. Rosenkranz K., Meier C. Umbilical cord blood cell transplantation after brain ischemia – from recovery of function to cellular mechanisms. Ann Anat. 2011; 193: 371–9.
119. Rosenkranz K., et al. Transplantation of human umbilical cord blood cells mediated beneficial effects on apoptosis, angiogenesis and neuronal survival after hypoxic-ischemic brain injury in rats. Cell Tissue Res. 2012; 348: 429–38.
120. McDonald C.A., et al. Effects of umbilical cord blood cells, and subtypes, to reduce neuroinflammation following perinatal hypoxic-ischemic brain injury. J Neuroinflamm. 2018; 15: 47.
121. van Velthoven C.T., Kavelaars A., van Bel F., Heijnen C.J. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain Behav Immun. 2010; 24: 387–93.
122. van Velthoven C.T., Kavelaars A., van Bel F., Heijnen C.J. Repeated mesenchymal stem cell treatment after neonatal hypoxia-ischemia has distinct effects on formation and maturation of new neurons and oligodendrocytes leading to restoration of damage, corticospinal motor tract activity, and sensorimotor function. J Neurosci. 2010; 30: 9603–11.
123. Nair S., et al. Neuroprotection offered by mesenchymal stem cells in perinatal brain injury: role of mitochondria, inflammation, and reactive oxygen species. J Neurochem. 2021; 158: 59–73.
124. Kaminski N., et al. Mesenchymal stromal cell-derived extracellular vesicles reduce neuroinflammation, promote neural cell proliferation and improve oligodendrocyte maturation in neonatal hypoxic-ischemic brain injury. Front Cell Neurosci. 2020; 14: 601176.
125. Herz J., et al. Interaction between hypothermia and delayed mesenchymal stem cell therapy in neonatal hypoxic-ischemic brain injury. Brain Behav Immun. 2018; 70: 118–30.
126. Robertson N.J., et al. Human umbilical cord mesenchymal stromal cells as an adjunct therapy with therapeutic hypothermia in a piglet model of perinatal asphyxia. Cytotherapy. 2021; 23: 521–35.
127. Bernardo M.E., Fibbe W.E. Mesenchymal stromal cells and hematopoietic stem cell transplantation. Immunol Lett. 2015; 168: 215–21.
128. Cotten C.M., et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. J Pediatr. 2014; 164: 973.e1–9.e1.
129. Tsuji M., et al. Autologous cord blood cell therapy for neonatal hypoxicischaemic encephalopathy: a pilot study for feasibility and safety. Sci Rep. 2020; 10: 4603.
130. Reiter R.J. Pineal melatonin: cell biology of its synthesis and of its physiological interactions. Endocr Rev. 1991; 12: 151–80.
131. Tarocco A., et al. Melatonin as a master regulator of cell death and inflammation: molecular mechanisms and clinical implications for newborn care. Cell Death Dis. 2019; 10: 317.
132. Ng K.Y., Leong M.K., Liang H., Paxinos G. Melatonin receptors: distribution in mammalian brain and their respective putative functions. Brain Struct Funct. 2017; 222: 2921–39.
133. Calvo J.R., González-Yanes C., Maldonado M.D. The role of melatonin in the cells of the innate immunity: a review. J Pineal Res. 2013; 55: 103–20.
134. Hardeland R. Melatonin and inflammation-story of a double-edged blade. J Pineal Res. 2018; 65: e12525.
135. Reiter R.J., et al. Melatonin as an antioxidant: under promises but over delivers. J Pineal Res. 2016; 61: 253–78.
136. Sun F.Y., et al. Neuroprotection by melatonin against ischemic neuronal injury associated with modulation of DNA damage and repair in the rat following a transient cerebral ischemia. J Pineal Res. 2002; 33: 48–56.
137. Vriend J., Reiter R.J. Melatonin feedback on clock genes: a theory involving the proteasome. J Pineal Res. 2015; 58: 1–11.
138. Curtis A.M., Bellet M.M., Sassone-Corsi P., O’Neill L.A. Circadian clock proteins and immunity. Immunity. 2014; 40: 178–86.
139. Robertson N.J., et al. Melatonin augments hypothermic neuroprotection in a perinatal asphyxia model. Brain. 2013; 136: 90–105.
140. Aridas J.D., et al. Melatonin augments the neuroprotective effects of hypothermia in lambs following perinatal asphyxia. J Pineal Res. 2021; 71: e12744.
141. Pang R., et al. Melatonin and/or erythropoietin combined with hypothermia in a piglet model of perinatal asphyxia. Brain Commun. 2020; 3: fcaa211.
142. Robertson N.J., et al. Melatonin as an adjunct to therapeutic hypothermia in a piglet model of neonatal encephalopathy: a translational study. Neurobiol Dis. 2019; 121: 240–51.
143. Robertson N.J., et al. High-dose melatonin and ethanol excipient combined with therapeutic hypothermia in a newborn piglet asphyxia model. Sci Rep. 2020; 10: 3898.
144. Jerez-Calero A., et al. Hypothermia plus melatonin in asphyctic newborns: a randomized-controlled pilot study. Pediatr Crit Care Med. 2020; 21: 647–55.
145. Aly H., et al. Melatonin use for neuroprotection in perinatal asphyxia: a randomized controlled pilot study. J Perinatol. 2015; 35: 186–91.
146. Fulia F., et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: reduction by melatonin. J Pineal Res. 2001; 31: 343–9.
147. Ahmad Q.M., Chishti A.L., Waseem N. Role of melatonin in management of hypoxic ischaemic encephalopathy in newborns: a randomized control trial. J Pak Med Assoc. 2018; 68: 1233–7.
148. Ahmed J., Pullattayil S.A., Robertson N.J., More K. Melatonin for neuroprotection in neonatal encephalopathy: a systematic review & meta-analysis of clinical trials. Eur J Paediatr Neurol. 2021; 31: 38–45.
149. Moreira G.A., Moraes Neto R., Ribeiro R.G., Crippa A.C.S. Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature. Rev Paul Pediatr. 2022; 41: e2021197.
150. Lafuente H., et al. Effects of cannabidiol and hypothermia on short-term brain damage in new-born piglets after acute hypoxia-ischemia. Front Neurosci. 2016; 10: 323.
151. Barata L., et al. Neuroprotection by cannabidiol and hypothermia in a piglet model of newborn hypoxic-ischemic brain damage. Neuropharmacology. 2019; 146: 1–11.
152. Garberg H.T., et al. Short-term effects of cannabidiol after global hypoxiaischemia in newborn piglets. Pediatr Res. 2016; 80: 710–8.
153. Garberg H.T., et al. High-dose cannabidiol induced hypotension after global hypoxia-ischemia in piglets. Neonatology. 2017; 112: 143–9.
154. Maiwald C.A., et al. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (Albino): study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). BMC Pediatr. 2019; 19: 210.